Infectious Diseases Pharmacy Specialty Review Course for Recertification, Workbook Chapters + RECERT Assessment Package (Cert # L219125)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 05/26/2021
Content Release Date: 06/23/2021
Expiration Date: 06/21/2022
Activity Type: Application-based
CE Credits: 25.00 (ACPE and BPS)
Activity Fee: $425 (ASHP member); $625 (non-member)

Accreditation for Pharmacists

The American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in infectious diseases pharmacy.

Activity Overview

This course is intended for BCIDPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

  • Review pertinent clinical topics and practice skills
  • List valuable resources for further self-study  

This online course consists of 15 activities (see table below) and provides up to 25 hours of continuing pharmacy education credit and/or recertification credit.

Recertification Credit*

Board certified pharmacists are eligible to receive up to 25 hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.  You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Infectious Diseases Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/ID-review 

These activities are part of the ASHP and ACCP professional development program for BCIDP recertification approved by the BPS. 

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. 

Learning Activity

ACPE Number

Credit

Hours

*Assessment Pass Point

Antimicrobial Stewardship

0204-9999-21-943-H01-P

1.50

76%

Upper Respiratory Tract Infections

0204-9999-21-944-H01-P

2.00

Lower Respiratory Tract Infections

0204-9999-21-945-H01-P

1.50

Group 1 Assessment

5.00

 

HIV Infection and AIDS

0204-9999-21-946-H02-P

2.00

76%

Infections of Reproductive Organs and Sexually Transmitted Diseases

0204-9999-21-947-H01-P

1.50

Opportunistic Infections in Immunocompromised Patients

0204-9999-21-948-H01-P

1.50

Group 2 Assessment

5.00

 

Gastrointestinal and Intra-abdominal Infections

0204-9999-21-949-H01-P

1.50

76%

Viral Hepatitis

0204-9999-21-950-H01-P

2.00

Tuberculosis and Other Mycobacterial Infections

0204-9999-21-951-H01-P

1.50

Group 3 Assessment

5.00

 

Cardiovascular Infections

0204-9999-21-952-H01-P

1.50

75%

Urinary Tract Infections

0204-9999-21-953-H01-P

1.50

Statistics, Evidence-based Medicine, and Research Design

0204-9999-21-908-H04-P

2.00

Group 4 Assessment

5.00

 

Bone and Joint Infections and Skin and Soft Tissue Infections

0204-9999-21-954-H01-P

1.50

80%

Central Nervous System Infections

0204-9999-21-955-H01-P

1.50

Clinical Microbiology

0204-9999-21-956-H01-P

2.00

Group 5 Assessment

5.00

 

Learning Objectives

After participating in this CPE activity, learners should be able to: 

Antimicrobial Stewardship
ACPE Number:0204-9999-21-943-H01-P

  • Outline components of an effective stewardship program.
  • Select appropriate resources; relevant accreditation, legal, regulatory, and safety requirements; and quality metrics related to infectious diseases.
  • Evaluate institutional treatment policies and pathways for compliance with antimicrobial stewardship guidelines, surveillance data, and best available evidence.
  • Assess the effectiveness of infection prevention strategies.
  • Identify metrics for evaluating the value of infectious diseases pharmacy services. 

Upper Respiratory Tract Infections
ACPE Number: 0204-9999-21-944-H01-P

  • Assess pharmacotherapies for upper respiratory tract infections.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
  • Recommend modifications of patient-specific treatment plans based on efficacy and adverse effects.
  • Identify recommended immunizations and potential adverse effects. 

Lower Respiratory Tract Infections
ACPE Number: 0204-9999-21-945-H01-P

  • Assess pharmacotherapies for lower respiratory tract infections, including antimicrobialspectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend the most appropriate modifications of patient‐specific treatment plans based on efficacy, adverse effects, and follow‐up assessment.
  • Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with lower respiratory tract infections. 

HIV Infection and AIDS
ACPE Number: 0204-9999-21-946-H02-P

  • Assess pharmacotherapies for HIV‐infection and AIDS, including opportunistic infections.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • List recommended immunizations and screening guidelines for patients with HIV.
  • Recommend modifications of patient‐specific treatment plans based on efficacy, drug interactions, immunologic or virologic response, and adverse effects.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results related to HIV infection.
  • Evaluate a plan to facilitate transitions of care. 

Infections of Reproductive Organs and Sexually Transmitted Diseases
ACPE Number: 0204-9999-21-947-H01-P

  • Assess pharmacotherapies for infections of reproductive organs and sexually transmitted diseases.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Identify recommended screening guidelines for sexually‐transmitted diseases.
  • Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Summarize key considerations in effective patient and caregiver education and counseling techniques. 

Opportunistic Infections in Immunocompromised Patients
ACPE Number: 0204-9999-21-948-H01-P

  • Assess the advantages and disadvantages of pharmacotherapies for opportunistic infections in immunocompromised patients, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
  • Identify preventative therapies in immunocompromised patients. 

Gastrointestinal and Intra-abdominal Infections
ACPE Number: 0204-9999-21-949-H01-P

  • Assess pharmacotherapies for gastrointestinal and intra‐abdominal infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects. 

Viral Hepatitis 
ACPE Number: 0204-9999-21-950-H01-P

  • Assess pharmacotherapies for viral hepatitis, including relevant pharmacology and spectrum of activity.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, virus and genotype, and best available evidence.
  • Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
  • Recommend modifications of patient‐specific treatment plans based on efficacy, adverse effects, and drug interactions.
  • Summarize key considerations in effective patient and caregiver education and counseling techniques.
  • Identify screening guidelines and preventive therapies for viral hepatitis. 

Tuberculosis and Other Mycobacterial Infections
ACPE Number: 0204-9999-21-951-H01-P

  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
  • Recommend modifications of patient-specific treatment plans based on efficacy, adverse effects, and drug interactions.
  • Outline key considerations in effective patient and caregiver education and counseling techniques.
  • Identify screening guidelines and preventive therapies for tuberculosis and other mycobacterial infections.

Cardiovascular Infections
ACPE Number: 0204-9999-21-952-H01-P

  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Identify drug‐related problems associated with the therapeutic plan.
  • Recommend appropriate modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects.
  • Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with cardiovascular infections. 

Urinary Tract Infections
ACPE Number: 0204-9999-21-953-H01-P

  • Assess pharmacotherapies for urinary tract infections, including antimicrobial  spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
  • Identify infectious diseases for which notification of the Centers for Disease Control and Prevention is required. 

Statistics, Evidence-based Medicine, and Research Design
ACPE Number: 0204-9999-21-908-H04-P

  • Evaluate quality and appropriateness, with specific attention to study design, statistical analysis, internal/external validity, source of bias/confounders, and quality of conclusions and interpretation of graphs.
  • Explain why a statistical test is appropriate or not appropriate, based on the sample distribution, data type, and study design.
  • Interpret clinical and statistical significance for results from commonly used statistical tests.
  • Explain the strengths and limitations of different types of measures of central tendency (mean, median, and mode) and data spread (standard deviation, standard error of the mean, range, and interquartile range).
  • Evaluate odds ratio, risk/incidence rate, relative risk, number needed to treat, number needed to harm, and other risk estimates.
  • Determine whether the study applies to a specified patient population. 

Bone and Joint Infections and Skin and Soft Tissue Infections
ACPE Number: 0204-9999-21-954-H01-P

  • Assess the advantages and disadvantages of pharmacotherapies for bone and joint infections and skin and soft tissue infections, including antimicrobial spectrum of activity, pharmacokinetics, and
    pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Identify drug‐related problems associated with the therapeutic plan.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend appropriate modifications of patient‐specific pharmacotherapeutic plans based on
    efficacy and adverse effects.
  • Describe the etiology, diagnosis, and treatment of acute bacterial osteomyelitis and septic arthritis in pediatric patients. 

Central Nervous System Infections
ACPE Number: 0204-9999-21-955-H01-P

  • Assess pharmacotherapies for central nervous system infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Identify preventive therapies for central nervous system infections. 

Clinical Microbiology
ACPE Number: 0204-9999-21-956-H01-P

  • Explain the mechanisms of antimicrobial resistance among various pathogens.
  • Identify basic microbiology laboratory procedures.
  • Interpret laboratory and other diagnostic test results relevant to the diagnosis, management, and monitoring of patients with infectious diseases.
  • Evaluate biomedical literature with regard to study design and methodology specific to infectious diseases. 

Faculty 

Full faculty bios

Samuel L. Aitken, Pharm.D., M.P.H., BCIDP
Clinical Pharmacy Specialist - Infectious Diseases
The University of Texas MD Anderson Cancer Center
Houston, Texas 

Melissa Badowski, Pharm.D., M.P.H., BCPS,  BCIDP, AAHIVP, FCCP
Clinical Associate Professor
University of Illinois at Chicago, College of Pharmacy
Chicago, Illinois 

Elizabeth A. Coyle, Pharm.D., BCPS, FCCM
Associate Dean for Academic Affairs and Clinical Professor
University of Houston College of Pharmacy
Houston, Texas 

Eric Egelund, Pharm.D., Ph.D., AAHIVE
Clinical Assistant Professor
University of Florida
Jacksonville, Florida 

Kevin W. Garey, Pharm.D., M.S., FASHP*
Professor and Chair
University of Houston
Houston, Texas 

Julie Harting, Pharm.D., BCIDP
Associate Professor / Clinical Pharmacist Specialist, Infectious Disease
Sullivan University College of Pharmacy / University of Louisville Hospital
Louisville, Kentucky 

Angela Huang, Pharm.D., BCIDP
Clinical Pharmacy Specialist, Infectious Diseases/Antimicrobial Stewardship
HonorHealth John C. Lincoln Medical Center
Phoenix, Arizona 

Jerod Nagel, Pharm.D., BCIDP
Team Lead, Infectious Diseases and Antimicrobial Stewardship
University of Michigan Health System
Ann Arbor, Michigan 

J. Nicholas O'Donnell, Pharm.D., M.Sc., BCPS
Assistant Professor
Albany College of Pharmacy and Health Sciences
Albany, New York 

Natasha Pettit, Pharm.D., BCIDP, BCPS
Infectious Diseases Clinical Pharmacy Specialist
University of Chicago Medicine
Chicago, Illinois 

Jason J. Schafer, Pharm.D., M.P.H., BCIDP, BCPS-AQ ID, AAHIVP*
Professor and Vice Chair, Department of Pharmacy Practice
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania 

Kayla R. Stover, Pharm.D., BCIDP, BCPS, FCCP, FIDSA*
Associate Professor
University of Mississippi School of Pharmacy
Jackson, Mississippi 

Marylee Worley, Pharm.D., BCIDP, BCPS
Assistant Professor
Nova Southeastern University College of Pharmacy
Fort Lauderdale, Florida 

Evan  Zasowski, Pharm.D., M.P.H., BCIDP, BCPS*
Assistant Professor
Touro University California College of Pharmacy
Vallejo, California 

*Content matter experts 

Reviewers

Kristi N. Hofer, Pharm.D.
Susan R. Dombrowski, M.S., RPh 

Field Testers

Bashayer  Al Shehail, Pharm.D., BCIDP
Anas Al-Homran, Pharm.D, BCPS, BCCCP, BCIDP, SIDP
Nathan Batchelder, Pharm.D., BCPS, BCIDP
Sharon Blum, Pharm.D., BCIDP
John Bomkamp, Pharm.D., BCIDP, AAHIVP
Andrea Boyce, Pharm.D., BCIDP
Travis Carlson, Pharm.D., BCIDP
Dev Chatterji, Pharm.D., BCPS, BCIDP
Anthony Chiang, Pharm.D., BCIDP
Justine Choe, Pharm.D., BCIDP
Robbie Christian, Pharm.D., BCIDP, AAHIVP
Wei Teng Chung, MClinPharm, BCPS
Peter Colley, Pharm.D., BCPS-AQ ID, AAHIVP
Yewande Dayo, Pharm.D., BCIDP
Armisha Desai, Pharm.D., BCIDP
Chris Destache, Pharm.D., BCIDP
Alex Dominguez, Pharm.D., MAS, BCPS, BCIDP
Danielle Dufresne, Pharm.D.
Mariesa Durrant, Pharm.D., BCIDP
Reem Elajez, Pharm.D.
Yehia Elkhawly, Pharm D, BCPS, BCIDP
Mercedes Fraga, Pharm.D., BCPS, BCCCP, BCIDP
Riane Ghamrawi, Pharm.D., BCPS, BCIDP
Lina Hamid, Pharm.D., BCIDP
Stephanie Harding, Pharm.D., BCPS-AQ ID
Tara Harpenau, Pharm.D., BCIDP
Jillian Hayes, Pharm.D., BCIDP
Rebecca Jayakumar, Pharm.D., BCIDP
Scott Johns, Pharm.D., BCPS, BCIDP
Caroline Jozefczyk, Pharm.D., BCIDP
Wissam  Kabbara, B.S. Pharm, Pharm.D, BCPS-AQ ID
Jacquelyn  Koo, Pharm.D., BCIDP
Travis Kremmin, Pharm.D., BCPS, BCPID
Cassie Kuppelweiser, Pharm.D., BCIDP, AAHIVP, CPP
Yousef Lafi, Pharm.D., BCIDP, AAHIVP
Bradley Lauver, Pharm.D., BCPS, BCIDP
Siok Ying Lee, BCPS, AQ ID
Alison Lew, Pharm.D., BCIDP
Paul  Lewis, Pharm.D., BCPS-AQID
Rosanna Li, Pharm.D., BCIDP
Ann Lloyd, Pharm.D., BCPS-AQ ID, BCIDP
Christine MacBrayne, Pharm.D., MSCS, BCIDP
Alice Margulis, Pharm.D., BCIDP
Kassandra Marsh, Pharm.D., BCIDP
Brian Maynard, Pharm.D., BCIDP
Kari McCracken, Pharm.D., MBA, BCPS, BCIDP
Lacie McKamey, Pharm.D., BCPS, BCIDP
Krutika Mediwala, Pharm.D., BCPS, BCIDP
Andrew Merker, Pharm.D., BCPS, BCIDP
Ching Zin Ngua, Pharm.D., BCIDP
Clara Ni, Pharm.D., BCIDP
Alexander Novin, Pharm.D., BCPS, BCIDP
Pratish Patel, Pharm.D., BCIDP, AAHIVP
Radhika Polisetty, Pharm.D., BCIDP, BCPS, AAHIVP
Leonor  Rojas , Pharm.D, BCPS, BCIDP
Julia Sapozhnikov, BCIDP
Justin Schmetterer, Pharm.D., PhC, BCIDP
Julia Sessa, Pharm.D., BCIDP
Punit Shah, Pharm.D., BCPS, BCIDP
Stephanie Shulder, Pharm.D., BCIDP
Jessica Sobnosky, Pharm.D., BCPS, BCIDP
Caroline Tee, Pharm.D. , BCPS, BCCCP, BCIDP
Mary Ullman, Pharm.D., BCPS, BCIDP
Jill Waldhoff, Pharm.D., BCPS, BCIDP
Marissa Walsh, Pharm.D., BCPS-AQ ID
Lynn Wardlow, Pharm.D., MBA, BCPS, BCIDP
Kelly Williamson, Pharm.D., BCIDP
Rony Zeenny, Pharm.D., MPH, BCPS-AQ ID, FASHP
Anna Zhou, Pharm.D., BCIDP
Yvonne Zhou, BCPS, MSC

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Kevin Garey: Research support, Merck & Co.
  • Jason J. Schafer: Research grant recipient and advisory board, Merck; research grant recipient, Gilead; advisory board, ViiV 

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity. 

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP and ACCP. 

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.